Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes
Authors:
Open Access
- 12 April 2025
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 221, 115404
Abstract
No abstract availableKeywords
Funding Information
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBER/EHD25PI02)
- Spanish Association Against Cancer Scientific Foundation (RETO \u2013 PRYCO234831REIG)
- Carlos III Health Institute (PI18/0358, PI15/00145, PI22/01427, PMP22/00054, PI22/00705, FI19/00222)
- Generalitat de Catalunya
- Societat Catalana de Digestologia
- Asociación Española para el Estudio del Hígado
This publication has 18 references indexed in Scilit:
- Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenibInternal and Emergency Medicine, 2024
- Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumoursJournal of Hepatology, 2023
- Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus BevacizumabThe Oncologist, 2023
- Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real studyEuropean Journal of Cancer, 2022
- Tremelimumab plus Durvalumab in Unresectable Hepatocellular CarcinomaNEJM Evidence, 2022
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular CarcinomaNew England Journal of Medicine, 2020
- Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinomaJournal of Hepatology, 2020
- Systematic review with meta‐analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenibAlimentary Pharmacology & Therapeutics, 2019
- Myocarditis in Patients Treated With Immune Checkpoint InhibitorsJACC, 2018
- Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenibJournal of Hepatology, 2014